Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Portfolio Pulse from Vandana Singh
Roche Holdings AG inadvertently disclosed the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq versus Tecentriq alone for advanced or metastatic non-small cell lung cancer. The study remains ongoing and blinded to patients and investigators. The leaked data showed encouraging results, with tiragolumab plus Tecentriq well-tolerated and no new safety signals identified. More solid survival results are expected in Q1 2024.
August 23, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's inadvertent data leak reveals promising early results from its Phase 3 SKYSCRAPER-01 study. This could potentially boost investor confidence in the company's ongoing research and development efforts.
The leaked data shows promising early results from Roche's ongoing Phase 3 study. This could potentially boost investor confidence in the company's research and development efforts, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100